"El Hospital Universitario Fundación Jiménez Díaz, fundado hace más de 80 años por el Dr. Carlos Jiménez Díaz, cuenta con profesionales de prestigio que llevan a cabo labor asistencial, docente e investigadora. Así, mantiene acuerdos con la Universidad Autónoma de Madrid, entre otras entidades, y cuenta con su propia Escuela de Enfermería y su Instituto de Investigación Sanitaria. Con cerca de 80.000 metros cuadrados, está dotado de la más alta tecnología sanitaria y ofrece una amplia cartera de servicios."

During the past decade, START Madrid-FJD, Hospital Fundacion Jimenez Diaz conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 1 clinical trials were completed, i.e. on average, 3.7% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 1 clinical trials were completed. i.e. 7.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "START Madrid-FJD, Hospital Fundacion Jimenez Diaz" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Genentech, Inc." with 2 trials sponsored, "Genmab" with 2 trials sponsored, "Adaptimmune" with 1 trials sponsored and "Akamis Bio" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "START Madrid-FJD, Hospital Fundacion Jimenez Diaz" #1 collaborator was "BioNTech SE" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Eisai Inc." with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "START Madrid-FJD, Hospital Fundacion Jimenez Diaz" are "Solid Tumors" (9 trials), "Colorectal Cancer" (3 trials), "Advanced Solid Tumors" (2 trials), "Metastatic Melanoma" (2 trials) and "Non-small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "START Madrid-FJD, Hospital Fundacion Jimenez Diaz" in a lesser frequency.

Most popular intervention types in "START Madrid-FJD, Hospital Fundacion Jimenez Diaz" are "Drug" (22 trials), "Biological" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (8 trials), "Tocilizumab" (4 trials), "Obinutuzumab" (3 trials), "Bevacizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "START Madrid-FJD, Hospital Fundacion Jimenez Diaz" are 26 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "START Madrid-FJD, Hospital Fundacion Jimenez Diaz". undefined are not yet recruiting, 12 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in START Madrid-FJD, Hospital Fundacion Jimenez Diaz, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in START Madrid-FJD, Hospital Fundacion Jimenez Diaz, 23 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".